Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.
about
Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and ValidationPLK1, A Potential Target for Cancer TherapyAurora B kinase is a potent and selective target in MYCN-driven neuroblastomaSimultaneous suppression of the MAP kinase and NF-κB pathways provides a robust therapeutic potential for thyroid cancerThe contributions of the European Medicines Agency and its pediatric committee to the fight against childhood leukemiaVolasertib suppresses tumor growth and potentiates the activity of cisplatin in cervical cancer.Identification of synthetic lethality of PLK1 inhibition and microtubule-destabilizing drugs.Volasertib suppresses the growth of human hepatocellular carcinoma in vitro and in vivo.Cell cycle proteins as promising targets in cancer therapyThe GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models.Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor.Identifying novel therapeutic agents using xenograft models of pediatric cancer.Synergistic induction of apoptosis by a polo-like kinase 1 inhibitor and microtubule-interfering drugs in Ewing sarcoma cells.Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines.Improved therapy for neuroblastoma using a combination approach: superior efficacy with vismodegib and topotecanHigh levels of polo-like kinase 1 and phosphorylated translationally controlled tumor protein indicate poor prognosis in neuroblastomas.Eribulin alone or in combination with the PLK1 inhibitor BI 6727 triggers intrinsic apoptosis in Ewing sarcoma cell lines.Polo-like kinase 1 inhibition sensitizes neuroblastoma cells for vinca alkaloid-induced apoptosis.Targeting Polo-like kinase 1 in SMARCB1 deleted atypical teratoid rhabdoid tumor.Population Pharmacokinetics of Volasertib Administered in Patients with Acute Myeloid Leukaemia as a Single Agent or in Combination with Cytarabine.PLK1 expression and BI 2536 effects in childhood acute lymphoblastic leukemia.
P2860
Q26784048-62A32950-F708-4046-A93F-4798CF8439B0Q28078772-9780DFBE-9ED5-47B9-88C7-C21123F2A6FEQ35819646-B51B5966-CCD7-495A-8461-768DBD789D32Q36012586-538A567B-A93C-4AB3-80AA-37106C4FEE5EQ36267151-59878791-9663-4429-9A22-ACF0836226A1Q36516564-1C4EBEEF-320B-4D4E-AF28-4D8A51102C34Q36751562-FCC81EFD-C741-490A-9227-B8C63B05DCB1Q37447866-B7DFC93F-D8B5-43F7-94BC-6B689935339EQ37693690-AE5A4CC6-A874-4118-B54F-A7E5D8C9054CQ37701672-0CFD5DA6-49F8-4E0C-9A84-6BA497412630Q38824242-ECABBD12-B2ED-44A3-B835-EAD7B76CB2B5Q38837564-130EBAE0-1069-446A-9CDF-9416FF2B2191Q38844740-69AEF431-83EB-4F59-925F-603016DC8755Q39372427-E49F2D01-7F7A-4A40-8D76-6A865CF59D3AQ39954004-9AC3FFB7-D37E-4189-9B6A-76B28871676EQ40309145-F16C96DD-A4D4-4D21-8649-FF5BD191565DQ41592750-EC469D71-D98D-4715-882B-8D9AAC197D0BQ41819580-62C4DB6B-5EAC-4030-A6BA-BB5E881963BEQ47143476-7C2FCF6A-E9E8-41A8-B8E4-BFA160407530Q48253128-EEA3F472-E98F-4991-B2AA-77AFB1A21483Q53066951-B7E37B22-483E-4DAA-80EB-577075ED4CD3
P2860
Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Initial testing (stage 1) of t ...... c Preclinical Testing Program.
@ast
Initial testing (stage 1) of t ...... c Preclinical Testing Program.
@en
Initial testing (stage 1) of t ...... c Preclinical Testing Program.
@nl
type
label
Initial testing (stage 1) of t ...... c Preclinical Testing Program.
@ast
Initial testing (stage 1) of t ...... c Preclinical Testing Program.
@en
Initial testing (stage 1) of t ...... c Preclinical Testing Program.
@nl
prefLabel
Initial testing (stage 1) of t ...... c Preclinical Testing Program.
@ast
Initial testing (stage 1) of t ...... c Preclinical Testing Program.
@en
Initial testing (stage 1) of t ...... c Preclinical Testing Program.
@nl
P2093
P2860
P50
P356
P1476
Initial testing (stage 1) of t ...... ic Preclinical Testing Program
@en
P2093
Catherine A Billups
E Anders Kolb
Hernan Carol
John M Maris
Peter J Houghton
Raushan T Kurmasheva
Stephen T Keir
P2860
P304
P356
10.1002/PBC.24616
P577
2013-08-19T00:00:00Z